Mp14-03 a Method of Quantitative Classification of Metastatic Castration-Resistant Prostate Cancer and Its Signification and Application

You have accessJournal of UrologyProstate Cancer: Advanced (including Drug Therapy) II (MP14)1 May 2024MP14-03 A METHOD OF QUANTITATIVE CLASSIFICATION OF METASTATIC CASTRATION-RESISTANT PROSTATE CANCER AND ITS SIGNIFICATION AND APPLICATION Yong Wang, Zihao Liu, Yuan Shao, Yang Liu, Hua Huang, and Yuanjie Niu Yong WangYong Wang , Zihao LiuZihao Liu , Yuan ShaoYuan Shao , Yang LiuYang Liu , Hua HuangHua Huang , and Yuanjie NiuYuanjie Niu View All Author Informationhttps://doi.org/10.1097/01.JU.0001009428.69695.82.03AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVE: We designed this study to establish a precise and reliable CRPC typing method based on the corresponding molecular markers of three etiological mechanisms of CRPC, so as to improve CRPC individualized precision treatment. METHODS: CRPC patients were enrolled a biopsy for metastases and stained for IHC. The CRPC was classified according to the different molecular markers. ImageJ IHC Profiler quantitatively assessed the expression of different molecular markers in the tissues. IHC score was calculated using Z test. We defined four different CRPC phenotypes by IHC score as fellows, type 1 (AR-Score > Stem-Score and NE-Score), type 2A (Stem-Score >AR-Score >NE-Score), type 2B (Stem-Score >NE-Score >AR-Score), type 3 (NE-Score > AR-Score and Stem-Score). All enrolled patients were initiating treatment with either novel hormonal agents or docetaxel combined with carboplatin. We examined PSA progression-free survival (PSA-PFS), clinical/radiographic progression-free survival (rPFS) and overall survival (OS) among 4 type of patients with different treatment. RESULTS: According to the classification principles and methods, 67 CRPC patients enrolled in the study were devided into four types including 27 (40.3%) type 1 patients, 13 (19.4%) type 2A patients, 10 (14.9%) type 2B patients and 17 (25.4%) type 3 patients. Consistent with IHC classification, 54 mCRPC cases in SU2C/PCF Dream Team dataset were profiled and clustered into 3 gene types (AKR1C3/FKBP5, YAP1/CD44, NTS/ENO2/CHGA/SYP) and finally devided into 4 groups. We also preliminarily verified that there is good consistency between IHC and RNA typing. Among four types patients receiving NHA treatment, type 1 patients had slower disease progression. The median PSA-PFS, RPFS, and OS (20 months, 22 months, and 32 months, respectively) of type 1 patients were longer than other three types. Meanwhile, we found CD was more suitable for type 3 patients. The median PSA-PFS, RPFS, and OS of type 3 patients was 17 months, 18 months, and 28 months respectively. CONCLUSIONS: In this study, we establish an accurate simple and effective CRPC etiological classification method, and explore the relationship between disease progression, prognosis and precise treatment efficacy of CRPC. Source of Funding: This work was supported by the Urological Talent Incubation Project of the Second Hospital of Tianjin Medical University (2023ZDSYS06), the Youth Fund Project of the Second Hospital of Tianjin Medical University (2022ydey18), the Clinical Project of the Second Hospital of Tianjin Medical University (2020LC05, 2019LC02), the Central Guidance Local Science and Technology Development Fund Science and Technology Innovation Base Construction (22ZYJDSY00010). This study has been registered in the China Clinical Trial Registry with registration numbers ChiCTR2200066350 © 2024 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 211Issue 5SMay 2024Page: e220 Advertisement Copyright & Permissions© 2024 by American Urological Association Education and Research, Inc.Metrics Author Information Yong Wang More articles by this author Zihao Liu More articles by this author Yuan Shao More articles by this author Yang Liu More articles by this author Hua Huang More articles by this author Yuanjie Niu More articles by this author Expand All Advertisement PDF downloadLoading ...